Drug discovery: a job too complex for academia or industry alone?
05 January 2012 - 06 January 2012
A group of renowned scientists, policy- and decision-makers will be joining us in a series of six provocative discussion panels to honestly and openly debate the bottlenecks hindering innovation and real tangible results in drug discovery:
• How do we better select targets for Drug Discovery?
• What are the limitations of single molecule targets?
• How useful are animal models in Drug Discovery?
• What is limiting Drug Discovery in Academia?
• Is there any evidence that IP in early discovery is slowing down the development of new medicines?
• What are the consequences of pharma downsizing in UK? How does UK maintain its position in Drug Discovery?
Medical Sciences Teaching Centre - University of Oxford, UK
http://www.thesgc.org/events/symposia/DrugDiscov2012
4th Risk Evaluation and Mitigation Strategies Conference
19 January 2012 - 20 January 2012
The 4th Annual REMS Summit is a forum for senior level executives to gather and prepare for the changing landscape of REMS and FDA legislation. REMS and drug safety is a marathon race and the industry must stay ahead of the curve to ensure their drugs are staying compliant while ensuring accessibility and success in market. By attending this year’s event, the audience will benefit from one of the only conferences focused specifically on REMS and strategies to navigate the uncertainty, build a successful REMS program and streamline your clinical, safety, regulatory, and marketing sectors to successfully market your product.
The Westin, Arlington, VA, USA
http://exlpharma.com/events/4th-annual-risk-evaluation-and-mitigation-strategies
Novel Immunotherapeutics Summit
30 January 2012 - 31 January 2012
The Novel Immunotherapeutics Summit brings together experts from academia and industry to discuss cutting edge research, immuno-strategies and novel therapeutics against various diseases. Topics such as cytokines, inflammation, cancer immunotherapy, immunomonitoring, biomarkers, immunosuppression, allergy and asthma will be discussed at the summit. Receive updates on government policy, recent regulations, important investments and partnering strategies.
Paradise Point Resort & Spa, 1404 Vacation Road, San Diego, CA, USA
http://www.gtcbio.com/index.php?option=com_conference&file=home&cn=Novel%20Immunotherapeutics%20Summit&cid=55
10th Cytokines and Inflammation Conference
30 January 2012 - 31 January 2012
In 2012, the conference will cover ever-important topics such as the TNF family, the inflammasome, chemokines, costimulation and innate immunity. In addition, timely coverage will be devoted to areas of current rapid expansion, such as the IL-17 and Th17 fields and JAK/STAT kinases, at a time when phase 2 and even phase 3 studies are being conducted and reported in these areas. Intriguing recently discovered cytokines, such as IL-25, novel alarmins and novel IL-1 family members will also be covered.
Paradise Point Resort & Spa, San Diego, CA, USA
http://www.gtcbio.com/index.php?option=com_conference&file=home&cn=10th%20Cytokines%20and%20Inflammation%20Conference&cid=51
Scientific Considerations for Complex Drugs in Light of Established Regulatory Guidance
09 March 2012
The U.S. Food and Drug Administration (FDA) is currently working toward implementing the Biologics Price Competition and Innovation Act (BPCI) of 2009, which establishes an abbreviated approval pathway for biological products that are demonstrated to be "highly similar" to or "interchangeable" with a drug regulated under the Public Health Service Act. The yet-to-be finalized pathway raises questions that are far more complicated than those posed by traditional, small molecule generics including what type of pre-clinical/clinical data, safety, purity, immunogenicity and potency testing will be required by the FDA in the marketing application. Additionally, while current regulations do not make scientific distinctions between small-molecule drugs and non-biological complex drugs (NBCDs), NBCDs present many of the same scientific challenges to reproduce as biologics, and future regulations will likely be guided by lessons learned from the development of policy for biosimilars in the U.S. and abroad.
New York Academy of Science, NY, USA
http://www.nyas.org/Events/Detail.aspx?cid=eea36f38-0485-483b-84f4-5d87e65dd04f
Companion Diagnostics: from Early Drug Discovery to Clinical Application
01 May 2012
With recent heightened regulatory approval pressure, there needs to be a practical method available to demonstrate the effective performance of a treatment. In response, Companion Diagnostics are playing an increasingly critical role in the development of new therapeutic agents. As a result, research into key diagnostic technologies has become a hot topic, especially areas such as biomarkers, assay development and detection techniques. This has naturally led to the need to conduct diagnostic research in parallel with the early stages of drug discovery. This conference will highlight state-of-the-art scientific research and technologies, enabling the provision of tools for the development of Companion Diagnostics.
The Oxford Belfry, Oxford, UK
http://www.elrig.org/index.php/events/123-companion-diagnostics-2012/872-companion-diagnostics-2012
3rd Annual Pharmacovigilance 2012
31 August 2012
Pharmacovigilance 2012 will discuss the pressing concerns confronted with regard to drug safety, addressing the risks, time line, budget constrains, effectively tackling key challenges, overcoming trial agreement and site contract negotiation hurdles. Top pharmaceutical, biotech, and regulatory representatives will discuss the current complexities and controversies in pharmacovigilance and risk management throughout all phases of development
Hyatt Regency, Mumbai, India
http://www.virtueinsight.com/pharma/3rd-Annual-Pharmacovigilance-2012/
Biomarkers 2012
26 September 2012
Biomarker professionals will gather together to answer the all-important question- how can we get biomarkers to add value? How do you develop new medicines, which demonstrate real value through predictable outcomes in targeted patient groups? The event is a one day strategic conference tackling these questions and providing participants with a thorough review of the use of biomarkers, their effectiveness and their potential to transform R & D.
London Marriott Marble Arch Hotel, London, UK
http://www.virtueinsight.com/pharma/Biomarkers-2012/
The importance of (Bio)Pharmaceutical properties in successful drug design
04 October 2012
National Heart & Lung Institute (NHLI), Kensington, London, UK
http://www.smr.org.uk/smr/default.asp
Pharma Anti-Counterfeiting 2012
18 October 2012
This conference will gather government bodies, pharmaceutical companies and solution and technology providers to discuss the in-depth insights into the strategies and cutting edge technologies for pharmaceutical anti-counterfeiting.
London Marriott Marble Arch Hotel, London, UK
http://www.virtueinsight.com/pharma/Pharma-Anti-Counterfeiting-2012/
Molecular Interactions in Biopharmaceutical Formulations: Can Stability be Rationalised and Predicted?
30 October 2012
Formulation of biotherapeutics, leading to the development of stable and convenient drug products, is a crucial part of the biopharmaceutical process. The stability of biological molecules depends on a complex set of molecular interactions; understanding these interactions is critical for the success of the formulation development. MiBio 2012 will gather world leading experts from academia and from industry to take us from theoretical predictions of protein behaviour, through probing molecular interactions all the way to solving specific formulation issues of drug product candidates. The meeting will be interactive and whether you are a formulation scientist, process development scientist or an academic with interest in molecular interactions, we are convinced that you find this event extremely interesting and useful.
Trinity Centre, Cambridge, UK
http://www.formulation.org.uk/mibio-2012.html
Biologics World Taiwan 2012
12 November 2012
Biologics World Taiwan provides the ONLY biologics and biosimilars focused platform in Taiwan that brings together Taiwanese and international biopharma leaders, innovative biotechs, and technocrats.
Taipei, Taiwan
http://www.imapac.com/index.php?page=BiologicsWorldTaiwan2012
An Introduction to Open Innovation in Pharmaceuticals
12 December 2012
This masterclass will give delegates an insight into the fundamental concepts behind open innovation and the benefits and challenges of successful implementation in the pharmaceutical industry. Case histories from a range of different sectors will be used to illustrate these concepts. Attendees will gain an insight into the different perspectives of the players in open innovation and how these need to be taken into account in developing successful OI strategies.
tbc. Central London, UK
http://www.smi-online.co.uk/pharmaceuticals/uk/masterclass/an-introduction-to-open-innovation
2nd Allergy Drug Discovery
31 January 2013 - 01 February 2012
The conference will bring together industry, academia and government experts in the field of allergy, asthma and COPD. Experts will facilitate discourse on the challenges and opportunities for therapeutic and drug development for allergic diseases for the current and future generations. Topics will range from basic scientific research to biomarkers and clinical development. Novel immune targets, new therapeutic interventions, genetics, epigenetics and biomarkers in allergic diseases will be presented
The Westin Gaslamp Quarter San Diego, 910 Broadway Circle, San Diego, CA 92101
http://www.gtcbio.com/index.php?option=com_conference&file=home&cn=2nd%20Allergy%20Drug%20Discovery&cid=53